Canada Plans To Force Firms To Disclose Confidential Pricing Deals
Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.
You may also be interested in...
The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.
Public drug plan spending on medicines in Canada rose by nearly 10% in 2015-16, driven by a shift to the use of expensive patented drugs such as the direct acting antivirals for hepatitis C.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.